secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001689375-24-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q1 net income $23.5M; Vertex $75M milestone; DMD Phase 1 final cohort dosed; cash runway to Q2 2026
--------------------------------------------------------------------------------

- Net income $23.5M vs loss ($6.7M) Q1 2023; collaboration revenue $59.1M (up from $25.3M) on Vertex $75M milestone.
- Initiated dosing of 4th & final cohort of Phase 1 trial for ENTR-601-44 in DMD exon 44; data readout expected Oct 2024.
- Cash, cash equivalents & marketable securities $327.4M as of Mar 31, 2024; cash runway expected through Q2 2026.
- On track to submit regulatory apps in Q4 2024 for Phase 2 studies of ENTR-601-44 (DMD exon 44) and ENTR-601-45 (exon 45).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/0001689375-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/trda-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001689375-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer